HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

FDA Adcomm Recommends Paxlovid for Mild-to-Moderate COVID-19

Pfizer’s Paxlovid has received a nod from the US Food and Drug Administration’s (FDA’s) Antimicrobial Drug Advisory Committee for use in mild-to-moderate cases of COVID-19 in adults. The 16-1 vote came after Pfizer’s previous request for full approval hit a roadblock last year when the agency […]

more info 03/17/2023View Related Articles
Bookmark and Share

Exclusivity Loss Looms for Ten Key Drugs in 2023

As the year marches on, Fierce Pharma takes a look at 10 major drugs facing exclusivity losses in 2023. One of the most notable is Humira, AbbVie’s historically expensive blockbuster, which will face stiff competition from several upcoming biosimilars. Other drugs on the list include J&J’s […]

more info 03/17/2023View Related Articles
Bookmark and Share

Sanofi Cuts Insulin Prices and Sets Out-of-Pocket Price Cap

Hot on the heels of Novo Nordisk and Eli Lilly, Sanofi announced it will cut the price of its main insulin formulation, Lantus, in January of next year. Just outstripping the others, the cuts amount to a 78% price drop for the life-saving drug used by millions of people with diabetes. In addition, […]

more info 03/17/2023View Related Articles
Bookmark and Share

US CMS Releases Guidance on Upcoming Drug Price Negotiations

The pharma and biotech industry has waited with bated breath for more information on impending drug price negotiations with the US Centers for Medicare and Medicaid Services (CMS) that begin in 2026. The agency released its guidance on the process, laying out the process in detail. CMS has also put […]

more info 03/16/2023View Related Articles
Bookmark and Share

US HHS Picks 27 Drugs for Inflation Rebates

A recent rule will let the US Department of Health and Human Services (HHS) require drugmakers to pay back rebates on drugs that increase in price faster than inflation. The department has announced its list of the first 27 drugs to face this process, including therapeutics from pharma giants like […]

more info 03/15/2023View Related Articles
Bookmark and Share

Which Drugmakers Will Face US Drug Pricing Negotiations in 2026?

Although many likely contenders have been named, the first slate of drugs to face Medicare drug pricing negotiations in 2026 is yet to be determined. The first 10 drugs to be selected will be announced in September, likely including cancer drugs from AbbVie and Pfizer and BMS’s blood thinner […]

more info 03/14/2023View Related Articles
Bookmark and Share

Pharma’s Take on Drug Pricing Data Transparency in South Korea

Korea’s drug pricing policies are complex and lack transparency, according to Eli Lilly Korea’s General Manager Christopher J. Stokes. Stokes notes that he has spent considerable time talking with other pharma leaders, who generally agree with his take on the complicated nature of the South Korean […]

more info 03/13/2023View Related Articles
Bookmark and Share

Lilly and Boehringer’s Type II Diabetes Drug Gets Expanded Approval from FDA for Use in Children

Eli Lilly and Boehringer Ingelheim secured approval from the US Food and Drug Administration (FDA) to expand the indications of its diabetes drug Jardience. The new indications include children under 10 with type 2 diabetes, a growing population in recent years. The drug would be the first in its […]

more info 03/10/2023View Related Articles
Bookmark and Share

EMA and FDA Parallel Review Program Sees Slow Uptake

Pharma and biotech companies seeking entry into the US and EU markets may request advice from both agencies through the Food and Drug Administration (FDA) and European Medicines Agency (EMA) Parallel Scientific Advice (PSA) Program. However, few companies seem to be opting for the program, with only […]

more info 03/09/2023View Related Articles
Bookmark and Share

New US Bill Challenges Use of QALY in Drug Value Assessments

Quality-adjusted life years (QALY) is a metric widely used when determining the cost-effectiveness of a drug, often when deciding upon or recommending drug prices. A new bill was approved by the US House Energy and Commerce Health Subcommittee that would, if passed, end the practice of using QALY in […]

more info 03/09/2023View Related Articles
Bookmark and Share

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 97
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • Sr. Manager of HEOR Analytics
  • Manager of Commercial Analytics
  • Assistant Director - Oncology Strategy & Communications (Remote)
  • Senior Director - Evidence Generation & Value Communications (Remote)
  • Medical Writer
 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists